AbbVie Inc. ABBV
264.34
(0.78)
(0.29%)
as of 25 Sep
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
AbbVie Inc. (ABBV) Net income
AbbVie Inc.'s net income for fiscal 2025 was $4.2B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $6.3B. Over the past ten years it has ranged from $4.2B (fiscal 2025) to $11.8B (fiscal 2022) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. AbbVie Inc. ranks 9th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $4.2B | (1.24%) |
| FY2024 | $4.3B | (12.05%) |
| FY2023 | $4.9B | (58.86%) |
| FY2022 | $11.8B | 2.56% |
| FY2021 | $11.5B | 149.87% |
| FY2020 | $4.6B | (41.36%) |
| FY2019 | $7.9B | 38.60% |
| FY2018 | $5.7B | 7.12% |
| FY2017 | $5.3B | (10.82%) |
| FY2016 | $6.0B | 15.73% |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $3.6B | 418.79% |
| Mar 2026 | $697.0M | (61.60%) |
| Dec 2025 | $1.8B | 865.43% |
| Sep 2025 | $188.0M | (80.02%) |
| 42 more quarters | Free account |
Against its own ten years
Low $4.2B
High $11.8B
Ten-year median
$5.3B
Current reading's percentile
9
Net income against peers
| Company | Net income |
|---|---|
| LLY Eli Lilly and Company compare | $26.7B |
| JNJ Johnson & Johnson compare | $21.0B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| AMGN Amgen Inc. compare | $8.7B |
| ABBV AbbVie Inc. | $6.3B |
| PFE Pfizer Inc. compare | $4.4B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ABBV
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement